Evidence map›Paper›PMID 34687279›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis.

Sandro Satta, Angela Lai, Susana Cavallero, Cayden Williamson, Justin Chen, Ana M Blázquez-Medela, Mehrdad Roustaei, Barbara J Dillon, Nureddin Ashammakhi, Dino Di Carlo and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Biomimetic cell membrane-coated poly(lactic-Bioengineering & translational medicine · 2023
    Review
  5. Review
  6. Review
  7. Review
  8. Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Sandro SattaDivision of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.ORCID 0000-0002-0827-8862
Angela LaiDivision of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Susana CavalleroDivision of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.ORCID 0000-0001-8974-6519
Cayden WilliamsonDepartment of Bioengineering, Henry Samueli School of Engineering & Applied Science, University of California, Los Angeles, CA, 90095, USA.ORCID 0000-0003-2885-5177
Justin ChenDepartment of Bioengineering, Henry Samueli School of Engineering & Applied Science, University of California, Los Angeles, CA, 90095, USA.
Ana M Blázquez-MedelaDivision of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Mehrdad RoustaeiDepartment of Bioengineering, Henry Samueli School of Engineering & Applied Science, University of California, Los Angeles, CA, 90095, USA.
Barbara J DillonDivision of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Nureddin AshammakhiDepartment of Bioengineering, Henry Samueli School of Engineering & Applied Science, University of California, Los Angeles, CA, 90095, USA.
Dino Di CarloDepartment of Bioengineering, Henry Samueli School of Engineering & Applied Science, University of California, Los Angeles, CA, 90095, USA.
Zhaoping LiDepartment of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, 90073, USA.
Ren SunDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.
Tzung K HsiaiDivision of Cardiology, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, 90095, USA.ORCID 0000-0003-1734-0792
University of California, Los Angeles · US

Funding

Shear Stress and Light-Sheets to Study Cardiac TrabeculationR01HL129727 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K, MARSDEN, ALISON L · 2015 to 2024
$3.5M
Electronica Impedance to Access Metabolically Active PlaqueR01HL118650 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSIAI, TZUNG K · 2014 to 2022
$3.3M
Micro-Sensors to Study Electrical and Mechanical Coupling of Injured MyocardiumR01HL111437 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HSIAI, TZUNG K, XU, XIAOLEI · 2012 to 2020
$3.1M
Intravascular Deployment of a Wirelessly Powered Micro-PacerR01HL149808 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tzung K Hsiai · 2020 to 2026
$2.8M
iDISCOVER: Integrated Data Science Training in CardioVascular MedicineT32HL139450 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUI, ALEX, PING, PEIPEI · 2018 to 2022
$1.3M
Exercise-Induced Shear Stress Modulates Metabolic Pathways for Vascular Repair and ProtectionI01BX004356 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI HSIAI, TZUNG K · 2019 to 2024
–
BLRD VA I01 BX004356NHLBI NIH HHS R01 HL111437NHLBI NIH HHS R01 HL118650NHLBI NIH HHS R01 HL129727NHLBI NIH HHS R01 HL149808NHLBI NIH HHS T32 HL139450NIH HHS BX004356NIH HHS HL111437NIH HHS HL118650NIH HHS HL129727NIH HHS HL149808
6 · The paper itself

Abstract

Activation of endothelial cells following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is thought to be the primary driver for the increasingly recognized thrombotic complications in coronavirus disease 2019 patients, potentially due to the SARS-CoV-2 Spike protein binding to the human angiotensin-converting enzyme 2 (hACE2). Vaccination therapies use the same Spike sequence or protein to boost host immune response as a protective mechanism against SARS-CoV-2 infection. As a result, cases of thrombotic events are reported following vaccination. Although vaccines are generally considered safe, due to genetic heterogeneity, age, or the presence of comorbidities in the population worldwide, the prediction of severe adverse outcome in patients remains a challenge. To elucidate Spike proteins underlying patient-specific-vascular thrombosis, the human microcirculation environment is recapitulated using a novel microfluidic platform coated with human endothelial cells and exposed to patient specific whole blood. Here, the blood coagulation effect is tested after exposure to Spike protein in nanoparticles and Spike variant D614G in viral vectors and the results are corroborated using live SARS-CoV-2. Of note, two potential strategies are also examined to reduce blood clot formation, by using nanoliposome-hACE2 and anti-Interleukin (IL) 6 antibodies.

Indexed as

Angiotensin-Converting Enzyme 2AntibodiesBlood CoagulationCOVID-19Endothelial CellsFibrinGenetic VectorsHumansInterleukin-6LiposomesMicrofluidicsMutationNanoparticlesPlatelet AggregationSARS-CoV-2Spike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2AntibodiesFibrinInterleukin-6LiposomesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2inflammationmicrofluidic chipSARS-CoV-2thrombosis

Identifiers

PMID34687279
PMCPMC8646611
OpenAlexW3205965700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.